Expanded Supply Line Options for Clinical Diagnostics Industry

Global life science industry critical materials supplier Biosynth Carbosynth has acquired Aalto Bio Reagents (Dublin), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.

Dr Urs Spitz, CEO and President of Staad-based Biosynth, said, “This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.”

Philip Noone, CEO of Aalto, added, “We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s product and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.”

More information online